Slide 1: Investor Presentation Q4 FY15 Earnings Release
Investor Presentation Q4 FY 15 Earnings Release 29 May 2015 Investor Presentation Q4 FY 15 Earnings Release Confidential 1
Slide 2: Disclaimer
Disclaimer Except for the historical information contained herein, statements in this presentation and the subsequent discussions may constitute "forward-looking statements". These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results t
Slide 3: Financial Performance Summary
Financial Performance Summary Q4 FY 2014-15 FY 2014-15 Consolidated Consolidated Actuals vs Q4 FY Actuals vs FY 14 (Rs Cr.) 14 (Rs Cr.) Revenue 3,093 22.1% 11,345 11.5% Domestic 1,086 20.7% 4,825 18.0% Sales Export Sales 1,895 22.8% 6,058 5.6% EBITDA 508 24.0% 2,162 1.3% EBITDA % 16.4% 0.3% 19.1% -1
Slide 4: Performance Summary (1/2)
Performance Summary (1/2) Area Highlights • Consolidated Q4 FY 2014-15 Sales: Rs. 3,093 Cr, 22.1% above Q4 FY 2013-14 • Consolidated Q4 FY 2014-15 EBITDA: Rs. 508 Cr, 24% above Q4 FY 2013-14 Financial • Consolidated FY 2014-15 Sales: Rs. 11,345 Cr, 11.5% above FY 2013-14 Performance • Consolidated F
Slide 5: Performance Summary (2/2)
Performance Summary (2/2) Area Highlights • R&D expense 6.2% of revenue for FY 2014-15 • >200 formulation development projects underway • Stempeutics filed with DCGI for its lead product Stempeucel; Received ATMP classification from R&D Pipeline EMA and granted process patent in China and North Amer
Slide 6: India (Rx and Gx)
India (Rx and Gx) India business momentum continues India (Rx and Gx) – Market share of 5.27% in FY 2014-15. Rs. crore Strong momentum into FY 2015-16 with 4,683 April 2015 market share at 5.57% (Source: IMS data) 18% – Continue to outpace market growth- 3,974 20% vs 12% for industry (Source: IMS
Slide 7: International (Rest of the World)
International (Rest of the World) International business contributed 25% to overall sales Strong Q4 FY 2014-15 growth of 33%; 9% growth in sales for the year International (Rest of the World) Business de-risked via front end build in 17 $ Mn select markets eg. Yemen, Iran, Sri Lanka, 459 Myanm
Slide 8: South Africa
South Africa South Africa ZAR Mn South Africa business contributed 14% to overall sales (on a consolidated basis) 4% 2,658 2,565 4% growth in sales for the year – based on like for like sales Private market contributed ~73% to overall South Africa topline; and grew at 9% in FY 2014-15. Trans
Slide 9: North America
North America North America North America business contributed 8% to overall sales $ Mn 20% growth in sales for the year 148 12 filings in FY 2014-15: Portfolio focus on 20% respiratory, oncology and anti-infectives 123 Out-licensing deal with Salix for ‘Rifaximin Complexes’ patent family co
Slide 10: Europe
Europe Europe Europe business contributed 4% to overall $ Mn sales 24% decline in sales for the year – MEDA (Dymista) one off in prior year 94 – Decline in partner business -24% – Good momentum in direct to market 71 (front end) business Launch of Salmeterol Fluticasone in select European mark
Slide 11: API and Veterinary
API and Veterinary API and Veterinary API and Veterinary contributed 6% to overall $ Mn sales 138 -18% 18% decline in sales for the year 113 Growth in captive API requirements reflecting in lower sales to third party Continue to drive cost efficiencies and process improvement initiatives 3
Slide 12: Priorities going forward
Priorities going forward 1. Deliver strong financial performance Revenue, EBITDA, cash flow growth Execute Respiratory and CGA growth strategy Cost optimization- Direct and Indirect spends 2. Build organization health Drive strong sales + profit growth Strengthen operations backbone with rig